Lichenoid and Autoimmune Oral Lesions

Lichenoid and autoimmune oral lesions are immune-mediated diseases of the oral mucosa in which the body's own immune response damages the mucosal epithelium. The prototype is oral lichen planus, a chronic T-cell-mediated condition producing white striae, erythema, or erosion; this group also includes lichenoid reactions to drugs or dental materials and the autoimmune blistering diseases mucous membrane pemphigoid and pemphigus vulgaris.

Definition

Lichenoid and autoimmune oral lesions are immune-mediated mucosal diseases characterised by a cytotoxic or autoantibody-driven attack on the oral epithelium, producing lichenoid (white, reticular, or erosive) or blistering lesions; oral lichen planus is the archetype.

Scope

The topic covers oral lichen planus and its clinical forms (reticular, erosive, atrophic), oral lichenoid lesions distinguished by an identifiable trigger, and the principal immunobullous diseases affecting the mouth. It addresses the immune mechanism of basal-cell injury, the question of malignant potential, and the diagnostic role of biopsy and immunofluorescence. It is descriptive reference material rather than treatment guidance.

Core questions

• How does oral lichen planus differ clinically and microscopically from an oral lichenoid reaction?
• What immune mechanisms drive basal-cell injury in lichenoid disease?
• Which autoimmune blistering diseases affect the oral mucosa and how are they diagnosed?
• What is the evidence on malignant transformation of oral lichen planus?

Key concepts

• Oral lichen planus (reticular, erosive, atrophic forms)
• T-cell-mediated basal keratinocyte injury
• Oral lichenoid reactions to drugs and dental materials
• Mucous membrane (cicatricial) pemphigoid
• Pemphigus vulgaris
• Direct immunofluorescence in diagnosis
• Potentially malignant disorder status

Mechanisms

In oral lichen planus, cytotoxic T lymphocytes accumulate at the epithelial-connective tissue interface and trigger apoptosis of basal keratinocytes, producing the characteristic band-like inflammatory infiltrate and basal-cell destruction seen on biopsy. When a specific trigger such as a drug or a dental restorative material can be identified, the same histological pattern is termed an oral lichenoid reaction. The immunobullous diseases differ in target: in pemphigus vulgaris, autoantibodies against desmosomal proteins disrupt cell-to-cell adhesion within the epithelium (intraepithelial blistering), whereas in mucous membrane pemphigoid, autoantibodies against the basement-membrane zone cause subepithelial separation. Direct immunofluorescence helps distinguish these conditions.

Clinical relevance

Because lichenoid and autoimmune lesions can erode, cause pain, and in the case of oral lichen planus are classified among potentially malignant disorders, accurate diagnosis and follow-up are emphasised; biopsy and immunofluorescence are central to distinguishing them. This entry explains how these conditions are categorised and diagnosed; it is reference material and not a basis for managing an individual.

Epidemiology

Oral lichen planus affects an estimated one to two percent of adults, more often women and those in middle age, and is among the more common chronic oral mucosal diseases; the immunobullous diseases are considerably rarer but frequently involve the mouth, with mucous membrane pemphigoid often presenting as desquamative gingivitis.

Evidence & guidelines

Evidence on oral lichen planus includes international consensus reports addressing diagnosis and malignant transformation and randomised trials of topical therapies, alongside oral pathology textbooks; classification of oral lichen planus as a potentially malignant disorder reflects observational and review evidence, and management lies outside this reference entry.

History

Lichen planus was described in the nineteenth century, and twentieth-century oral medicine characterised its oral forms, distinguished idiopathic lichen planus from lichenoid reactions with identifiable triggers, and, through international consensus efforts, debated its classification and malignant potential.

Debates

Does oral lichen planus undergo malignant transformation?

Whether and how often oral lichen planus progresses to oral squamous cell carcinoma is debated, complicated by difficulty separating true lichen planus from lichenoid dysplasia; international consensus work has examined the diagnostic criteria and transformation risk without fully settling the question.

Seminal works

• lodi-2005
• thongprasom-2007
• neville-2016

Frequently asked questions

What is the difference between oral lichen planus and an oral lichenoid reaction?

They share the same immune-mediated histological pattern, but an oral lichenoid reaction has an identifiable trigger such as a drug or a dental material, whereas oral lichen planus is idiopathic; removing the trigger can resolve a lichenoid reaction.

Why is oral lichen planus monitored over time?

Oral lichen planus is classified among the oral potentially malignant disorders, so periodic clinical review is recommended; this entry describes that classification rather than prescribing a surveillance schedule for any individual.